AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available

... of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infraction have occurred. The dosage should ... In clinical trials of patients with hypertension and angina pectoris the most common adverse events reported with immediate-release metoprolol ...

Different treatment options in chronic coronary artery disease

... to the analyses of registries, which provide complementary data. Thus PCI or ACB is advisable in those patients who still suffer from angina pectoris under drug treatment or for whom relevant ischemia has been demonstrated by non-invasive methods. According to the authors, the main indication for ...

University of the Basque Country team develop nano-hydrogels capable of detecting cancer cells

... short time , but very large molecules cannot be injected because they may cause obstruction or problems on the organism such as, for example, angina pectoris and even heart attack. The essential condition for their use in humans is that these particles have to be sufficiently small so as not to obstruct ...

Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared?

... heart due to CVD affects the conduction system of the heart. Depending on the level of malfunction, the manifestation of outcome varies from angina pectoris to ventricular arrhythmia. Demographics such as the increasing baby-boomer population, sedentary lifestyle, and increased disorders such as ...

Effectiveness Of Drug-Releasing Coronary Stents

... two drugs, which were used to coat stents in patients with new coronary artery lesions. The trial called REALITY examined 1,386 patients with angina pectoris in 90 hospitals in Europe, Latin America, and Asia between August 2003 and February 2004. The patients were randomly assigned either a ...

Nifedipine Found To Effective For Patients With Angina

... Angina pectoris is the most common symptom in patients with plaque build-up in their coronary artery. A recent study shows the heart medication // nifedipine (Adalat ...

pectoris in Medical Technology

Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test

... accounting for nearly 30-percent of all deaths. Cardiovascular disease has a number of forms but the most common are myocardial infarction and angina pectoris which affect the heart itself. There are well known environmental risk factors associated with cardiovascular disease such as smoking, diet, ...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

... release should avoid abrupt cessation of therapy. Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, is some cases, myocardial infarction have occurred. The dosage should be reduced gradually over a one-to-two-week period, and the patient should ...

Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint

... of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, use of coronary revascularisation and for angina pectoris with objective evidence of ischemia. AstraZeneca and AtheroGenics will now work together to fully analyse the full data set for AGI-1067, including ...

Calcium Channel Blocker Adalat GITS Offer Additional Benefits

... Lowering blood pressure helps reduce stroke and heart failure The ACTION-trial showed that adding nifedipine GITS to a best practice angina pectoris therapy significantly reduced the incidence of any stroke or TIA (28%) and the development of new overt heart failure (29%). Using an innovative ...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

... patients. In addition to its impact on overall cardiovascular events and stroke, Diovan demonstrated relative reductions of 65% in angina pectoris (recurring acute chest pain), 46% in heart failure and 81% in aortic dissection (separation of the wall layers in the body's main artery) compared to ...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

... FONT-FAMILY: Sabon">In addition to its impact on overall cardiovascular events and stroke, Diovan demonstrated relative reductions of 65% in angina pectoris (recurring acute chest pain), 47% in heart failure and 81% in aortic dissection (separation of the wall layers in the body’s main ...

pectoris in Medical Definition

Angor animi

... Angor animi (also referred to as angina animi [1] [2] , Gairdner's disease [2] and also angina pectoris sine dolore [2] ), is a term used in medicine to describe a person's perception that they are in fact dying. Most cases of angor animi are ...

Pathology

... heart disease - Hypertensive nephropathy - Secondary hypertension - Renovascular hypertension Ischaemic heart disease Angina pectoris - Prinzmetal's angina - Myocardial infarction - Dressler's syndrome Pulmonary circulation Pulmonary embolism - Cor pulmonale ...

pectoris in Medical Dictionary

Angina

... Angina pectoris Related Category: Pathology (nj´n ... y todas las opciones de tratamiento. Angina pectoris A feeling of tightness, heaviness, or pain in ... that supply blood to the heart . ANGINA pectoris - A REAL PAIN IN THE CHEST Question: I've had ...

Angina pectoris

... Angina pectoris Related Category: Pathology (nj´n ... an insufficient supply of oxygen . Angina pectoris (Stable Angina ) Arteriosclerosis ( ... Disease ) Coronary Artery Spasm ... ANGINA pectoris - A REAL PAIN IN THE CHEST Question: I've had ...

Aneurysm

... vessels or the heart . As an aneurysm increases in size, the sac tends to become thinner, and the risk of its breaking becomes greater. angina pectoris ... Aneurysm in the Brain Angina Angina - Stable Angina - Unstable ( Unstable Angina ) Angina - Variant ( Coronary Artery Spasm ) ... ...

Belching

... of bloating , as well as increased belching or passing of gas from the rectum . The person has chest pain that is often mistaken for angina pectoris ( cardiac pain ). Heartburn and difficulty belching are common. Symptoms usually get steadily worse. If the normal digestive action of the ...

Coronary Heart Disease

... Diabetic retinopathy ... 4 years, found that the overall incidence of coronary heart disease (i.e., myocardial infarction and/or angina pectoris ) was increased 1.17 times (95% confidence interval [CI], 1.04-1.31) compared to the general population. Can lifestyle changes reverse coronary ...

Croup

... voice box and windpipe. A condition, such as croup or diphtheria , in which spasm odic and painful suffocation or spasm s occur. 2. Angina pectoris . Abdominal angina is a condition that follows the first definition in that the sufferer typically has attacks of abdominal pain . Sudden ...

Diphtheria

... through 6 years of age. A condition, such as croup or diphtheria , in which spasm odic and painful suffocation or spasm s occur. 2. Angina pectoris . Abdominal angina is a condition that follows the first definition in that the sufferer typically has attacks of abdominal pain . The list ...

Disease

... s & Conditions Acute Mitral Incompetence ( Mitral Regurgitation , Acute ) Acute Mitral Insufficiency ( Mitral Regurgitation , Acute ) Angina pectoris (Stable Angina ) Aortic Coarctation (Coarctation of the Aorta ) ... Disease s & Conditions Index Comprehensive and reliable medical ...

Hearing

... information about the outside world and limits the child's ability to communicate with others. " Most of us think of heart pain (aka " angina pectoris ") upon hearing the term " angina . Conductive problems are those that disrupt the conduction of sound through the outer and middle ear (see ...

Heart Disease

... (sedentary lifestyle) ... 4 years, found that the overall incidence of coronary heart disease (i.e., myocardial infarction and/or angina pectoris ) was increased 1.17 times (95% confidence interval [CI], 1.04-1.31) compared to the general population. Cancer is the second leading cause of ...

More>>

pectoris in Biological Technology

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

... therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal ... therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal ...

CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina

... therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal ... therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal ...

Cardium Launches New AWARE Clinical Study Website

... ) The AWARE (Angiogenesis in Women with Angina pectoris who are not candidates for Revascularization) study, a Phase 3 ... is planned to enroll approximately 300 women with recurrent stable angina pectoris who are not candidates for revascularization and who are receiving optimal ...

CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug ...

CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug ...

CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug ...

CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug ...

CV Therapeutics Statement on Unsolicited Proposal From Astellas

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug ...

CV Therapeutics Reports 2008 Third Quarter Financial Results

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug ...

CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008

... prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. CV Therapeutics also has other clinical and preclinical drug ...